Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 3/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780268 | 1.00 | NPFFR1 (0.48) | NPFFR1NPFFR2SYKMEN1KMT2A | |
| SCHEMBL24940830 | 0.89 | MEN1 (0.43) | SYKMEN1KMT2ABACE1TACR1 | |
| SCHEMBL27139196 | 0.88 | OPRD1 (0.43) | SYKMEN1KMT2ABACE1TACR1 | |
| SCHEMBL743654 | 0.88 | TACR1 (0.43) | SYKMEN1KMT2ABACE1TACR1 | |
| SCHEMBL30732662 | 0.88 | MEN1 (0.42) | SYKMEN1KMT2ABACE1HTT | |
| SCHEMBL13738046 | 0.88 | SYK (0.44) | NPFFR1NPFFR2SYKMEN1KMT2A | |
| SCHEMBL23120954 | 0.87 | MEN1 (0.43) | NPFFR1NPFFR2SYKMEN1KMT2A | |
| SCHEMBL29862884 | 0.87 | MEN1 (0.43) | NPFFR1NPFFR2SYKMEN1KMT2A | |
| SCHEMBL14014442 | 0.86 | SYK (0.53) | NPFFR1NPFFR2SYKMEN1KMT2A | |
| SCHEMBL8569029 | 0.86 | PIK3R1 (0.45) | NPFFR1NPFFR2SYKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | NPFFR1 1407/4885NPFFR2 2316/4885SYK 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.